Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: dasotraline 4mgOther: Placebo
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT02734693
- Locations
- 🇺🇸
Avida Inc, Newport Beach, California, United States
🇺🇸Meridien Research, Bradenton, Florida, United States
🇺🇸Bayou City Research, Ltd, Houston, Texas, United States
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
- Conditions
- Recurrent Ovarian CarcinomaColorectal CarcinomaBRAF-Mutated MelanomaAdvanced Solid TumorsEGFR Positive Non-small Cell Lung Cancer
- Interventions
- Drug: TP-0903
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT02729298
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸US Oncology - Texas Oncology - Fort Worth, Fort Worth, Texas, United States
Dasotraline Binge Eating Disorder Extension Study
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 533
- Registration Number
- NCT02684279
- Locations
- 🇺🇸
Neuotrials Research, Inc., Atlanta, Georgia, United States
🇺🇸Boston Clinical Trials, Boston, Massachusetts, United States
🇺🇸Texas Center for Drug Development, Inc., Houston, Texas, United States
Dasotraline Binge Eating Disorder Study
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 319
- Registration Number
- NCT02564588
- Locations
- 🇺🇸
PCSD- Feighner Research, San Diego, California, United States
🇺🇸Capstone Clinical Research, Libertyville, Illinois, United States
🇺🇸Sunstone Medical Research, LLC, Medford, Oregon, United States
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Drug: APL-130277
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 496
- Registration Number
- NCT02542696
- Locations
- 🇺🇸
Keck Medical Center at USC, Los Angeles, California, United States
🇺🇸Clinical Trials, Inc., Little Rock, Arkansas, United States
🇺🇸UC Irvine Health Gottschalk Medical Plaza, Irvine, California, United States
An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate
- Conditions
- SCAR
- Interventions
- Other: Blood or Saliva
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT02520557
- Locations
- 🇺🇸
University of Pennsylvania Perlman School of Medicine, Philadelphia, Pennsylvania, United States
Alvocidib Biomarker-driven Phase 2 AML Study
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT02520011
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Morristown Cancer Center, Morristown, New Jersey, United States
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromesGlioblastoma MultiformeMelanomaNon-Small Cell Lung CancerOvarian CancerPancreatic CancerSarcomaRenal Cell Carcinoma
- Interventions
- Drug: DSP-7888 Dosing Emulsion
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02498665
- Locations
- 🇺🇸
Horizon Oncology Research, Lafayette, Indiana, United States
🇺🇸USOR - TX Oncology Austin, Austin, Texas, United States
🇺🇸USOR - TX Oncology Tyler, Tyler, Texas, United States
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
- Conditions
- Epilepsy
- Interventions
- Other: blood draw
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02491073
- Locations
- 🇺🇸
Mid-Atlantic Epilepsy Center, Bethesda, Maryland, United States
🇺🇸Consultans in Epilepsy & Neurology, PLLC, Boise, Idaho, United States
🇺🇸Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT02483247
- Locations
- 🇺🇸
Indiana University Health Goshen, Goshen, Indiana, United States
🇺🇸Louisiana State Univesity, New Orleans, Louisiana, United States
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada